ME · State regulatory reference

Maine.

Moderate

Maine follows a fairly standard framework with no distinctive state peptide/GLP-1 rule and no documented board enforcement located. Telehealth practice of medicine is governed by the Board of Licensure in Medicine's 'Telemedicine Standards of Practice' rule (02-373 C.M.R. ch. 6); a valid physician-patient relationship may be established via telemedicine 'if the standard of care does not require an in-person encounter,' and prescribing may occur in that encounter. Sterile compounding pharmacies are licensed under the Board of Pharmacy's 02-392 C.M.R. ch. 37, consistent with USP compounding standards; Maine has adopted no semaglutide/GLP-1-specific compounding restriction beyond federal 503A.

Last reviewed · 2026-05-25 · verified entry

Agencies

Medical board

Maine Medical Board

https://www.maine.gov/md/ ↗

Pharmacy board

Maine Board of Pharmacy

https://www.maine.gov/pfr/professionallicensing/professions/pharmacists/index.html ↗

TPC notes

Telehealth

Under 02-373 C.M.R. ch. 6, an initial visit and prescribing can occur via synchronous telemedicine without a prior in-person exam where the standard of care allows; prescribing 'based solely on an Internet request or Internet questionnaire' is prohibited, as is a telephonic-only evaluation absent a valid relationship.

Compounding

Maine licenses sterile compounding pharmacies under 02-392 C.M.R. ch. 37 and aligns with USP compounding standards; no Maine-specific GLP-1/semaglutide compounding prohibition beyond federal 503A limits was found.

Sources